Peptides DB
Research-centric peptide and protocol reference hub
Study 19 of 20Survodutide (BI 456906) literatureBioactive materials · Observational · Preclinical

A dual-targeting mRNA lipid nanoparticle restores ABCA1-dependent cholesterol homeostasis to promote repair of age-related bone defects.

The study suggests that targeting ABCA1 palmitoylation may help improve bone regeneration in aged cells, but further research is needed to confirm these findings in humans.

Read at Bioactive materialsAdd to compare

Where it sits

this study against the rest of the survodutide (bi 456906) corpus
1
Preclinical
9
Observational · this one
3
Open-label
5
Randomised
2
Reviews

Summary and findings

This study investigated the role of ABCA1 palmitoylation in bone marrow mesenchymal stem cell senescence and its impact on cholesterol homeostasis. The engineered lysosome-targeted depalmitoylase RAB7-APT2 was delivered via lipid nanoparticles to aged BMSCs. The treatment resulted in enhanced osteogenesis and improved bone regeneration in an aged rat defect model.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical

Abstract

The authors’ words, as Bioactive materials supplied them

Cholesterol regulates autophagy and aging, yet its role in bone marrow mesenchymal stem cell (BMSC) senescence remains unclear. We demonstrate that ABCA1 palmitoylation is associated with its lysosomal localization and lysosome-associated cholesterol transport, thereby contributing to autophagy inhibition, senescence, and impaired osteogenesis. However, directly perturbing ABCA1 palmitoylation impaired cholesterol efflux through plasma membrane-localized ABCA1, increased cellular cholesterol accumulation, and inhibited osteogenesis. To selectively depalmitoylate lysosomal ABCA1, we engineered a lysosome-targeted depalmitoylase, RAB7-APT2 (RA), by fusing RAB7 to APT2, the primary depalmitoylase of ABCA1. Aging-cell-targeted low-inflammatory liposomes were synthesized to deliver RA mRNA, yielding dual-targeted lipid nanoparticle (LNP@A). LNP@A selectively modulated lysosomal ABCA1 localization, reduced lysosomal cholesterol accumulation, restored autophagy, and alleviated senescence in aged BMSCs. Consequently, LNP@A enhanced osteogenesis in vitro and improved bone regeneration in an aged rat defect model. These findings reveal a role for ABCA1 spatial regulation in BMSC aging and provide a targeted strategy for age-related bone regeneration.

Background

This paper addresses the relationship between cholesterol regulation and bone marrow mesenchymal stem cell (BMSC) senescence, which is crucial for understanding age-related bone defects. Prior research has indicated that cholesterol influences autophagy and aging, but its specific role in BMSC function remained unclear. The study's findings may contribute to developing strategies for promoting bone repair in aging populations.

Methods

The study utilized an engineered lysosome-targeted depalmitoylase, RAB7-APT2, delivered via lipid nanoparticles (LNP@A) to aged BMSCs. The primary outcomes measured included cholesterol accumulation, autophagy restoration, and osteogenesis enhancement. The effects were evaluated in vitro and in an aged rat defect model.

Results

LNP@A reduced lysosomal cholesterol accumulation, restored autophagy, and alleviated senescence in aged BMSCs. The treatment enhanced osteogenesis in vitro and improved bone regeneration in the aged rat defect model.

Interpretation

The findings suggest that spatial regulation of ABCA1 may play a significant role in BMSC aging, aligning with previous literature on cholesterol's impact on cellular processes. However, the clinical significance of the observed effects remains uncertain, particularly given the reliance on an animal model. Limitations such as the absence of human data and specific quantitative outcomes may affect the applicability of these results in clinical practice.

Key findings

  • LNP@A reduced lysosomal cholesterol accumulation in aged BMSCs.
  • LNP@A restored autophagy in aged BMSCs.
  • LNP@A alleviated senescence in aged BMSCs.
  • LNP@A enhanced osteogenesis in vitro.
  • LNP@A improved bone regeneration in an aged rat defect model.

Limitations

  • rodent only, no human data
  • specific numerical data not provided
  • short follow-up in animal model
  • single-site study

Elsewhere in the Survodutide (BI 456906) corpus

CArchitecture-driven engineered lattice tetrahedral micro-scaffolds for extraskeletal osteogenesis.Biomaterials · 2026 · mean BV/TV values of 9.05-12.74% at 12 weeksAnimalDSurvodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.Cardiology in review · 2025 · Weight loss up to 18.7% in Phase 2 trials.reviewAEfficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026HumanDTracing the origins of de novo coronary collateral formation in cardiac repair.Science (New York, N.Y.) · 2026BSpatial non-uniformity of liver virtual non-contrast attenuation on dual-layer spectral CT: Impact of body habitus and peripheral right-lobe error.European journal of radiology open · 2026 · n=99 · Median absolute whole-liver TNC-VNC differences were 4.4 HU in the portal venous phase.HumanAComparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment of <i>Helicobacter pylori</i> infection: a prospective, multicenter, randomized controlled trial.Annals of medicine · 2026 · Eradication rate for KA group was 87.9% vs 80.3% for EA group in ITT analysis, p=0.092.Human